Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the possible benefits of treatment with different combinations of
the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with
ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of
improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type
of treatment most patients with this condition receive if they are not part of a clinical
study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus
olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal
antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of
PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged.
Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to
die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor
cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of
durvalumab, olaparib and cediranib may work better in increasing the duration of time that
the cancer does not progress compared to the usual treatment.